{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:57:02Z","timestamp":1698303422208},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6775,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1988,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A small group of elderly male patients received attenuated doses of daunomycin, cytosine arabinoside (Ara\u2010C), and 6\u2010thioguanine for treatment of myelodysplastic syndrome (MDS). Three patients had refractory anemia with excess blasts (RAEB), and two had chronic myelomonocytic leukemia (CMMoL). All five patients had developed severe transfusion requirements for platelets and red blood cells before therapy was begun. One patient developed necrosis of the cecum and expired 19 days after therapy, but the other four all showed substantial benefit from treatment. Three of those patients received multiple courses of chemotherapy which led to improvement in peripheral blood counts in each case. Duration of responses as noted by improvement in peripheral blood counts compared to pretreatment levels ranged from 1.5 to 9 months. Despite considerable improvement in peripheral blood parameters, some of the abnormal morphologic features of MDS persisted after each course of chemotherapy. These results obtained with attenuated chemotherapy schedules in a small group of patients are sufficiently encouraging to warrant an expanded phase II trial, which is under way at the University of Rochester Cancer Center.<\/jats:p>","DOI":"10.1002\/mpo.2950160208","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T17:55:12Z","timestamp":1171994112000},"page":"107-110","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: A preliminary report"],"prefix":"10.1002","volume":"16","author":[{"given":"Michael R.","family":"Owens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07524.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01157.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.1.85.85"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312293092602"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312293092617"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb07297.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312293092618"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312293092608"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850801)56:3<443::AID-CNCR2820560305>3.0.CO;2-Q"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197912)44:6<1976::AID-CNCR2820440603>3.0.CO;2-#"},{"key":"e_1_2_1_12_2","first-page":"981","article-title":"Phase 1 clinical trial of 13\u2010cis\u2010retinoic acid in myelodysplastic syndromes","volume":"67","author":"Gold EJ","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_13_2","first-page":"1369","article-title":"Phase 1\u201311 study of 13\u2010cis\u2010retinoic acid in myelodysplastic syndrome","volume":"69","author":"Greenberg BR","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1984.2.8.865","article-title":"Full dose daunorubicin (D), cytosine arabinoside (A) and thioguanine (T) (F\u2010DAT) vs. attenuated DAT (At\u2010DAT) in the treatment of acute non\u2010lymphocytic leukemia (ANLL) in the elderly: Results of a randomized ECOG trial","volume":"2","author":"Kahn SB","year":"1984","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91366-6"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb03906.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"The French\u2010American\u2010British (FAB) cooperative study: Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett JM","year":"1982","journal-title":"Br J Haematol"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950160208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950160208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:34:52Z","timestamp":1697859292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950160208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,1]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1988,1]]}},"alternative-id":["10.1002\/mpo.2950160208"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950160208","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,1]]}}}